Trial NCT04436276
Publication Sadoff J, N Engl J Med, 2021
Primary outcome on the report: The primary end points were the safety and re-actogenicity of each dose schedule. Follow-up visits to evaluate reactogenicity, safety, and im-munogenicity were scheduled on days 7, 28, and 71 after vaccination in each cohort.